Logan Lutton is an Associate Editor for Managed Healthcare Executive, with a focus on national healthcare issues in the United States. Logan's work has been featured in various publications, including Patient Care, Physicians Practice, Medical Economics, and Psychiatric Times. With a keen interest in healthcare technology, mental health, and medical research, Logan seeks to inform and engage readers on important topics in the healthcare industry.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Logan Lutton's articles predominantly focus on healthcare and pharmaceuticals, with an emphasis on government announcements and data-driven insights. His work also delves into mental health, digital health, and medical updates.
Given the substantial coverage of government announcements and cited data in his articles, Logan might be interested in pitches featuring expert analysis or commentary related to recent policy changes or new research findings within the healthcare industry. Additionally, he may respond well to pitches that offer innovative perspectives on digital health technology or insights into emerging trends in mental health treatment.
As a journalist focused nationally within the United States, professionals with expertise in U.S. healthcare policies & regulations or those involved in cutting-edge research at American institutions are likely to resonate more effectively with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Peter Wehrwein, Logan Lutton
Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.
By: Logan Lutton, Peter Wehrwein
There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.
By: Peter Wehrwein, Logan Lutton
Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery, shares the reasons why she chose to study metastatic breast cancer patients.
By: Logan Lutton
This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.
By: Logan Lutton
Popular menopause prescriptions such as Estradiol, Dotti, Premarin and Veozah will be available for cheaper using a GoodRx coupon.
By: Logan Lutton
The effects of breast cancer can remain long after the disease has left the body, serving as a traumatic daily reminder.
By: Logan Lutton
Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).
By: Logan Lutton
Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
By: Peter Wehrwein, Logan Lutton
David Maahs, M.D., M.A., Ph.D., explains the role that teamwork, targets, technology and tight control plays in type 1 diabetes management and why it’s best to intervene right after diagnosis.
If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date is August 21, 2025.
(833) 317-6278 
